2021 market access prospects for FranceIn the latest of a suite of features looking at the biggest markets in Europe, Leela Barham takes Share X2021 market access prospects for Francehttps://pharmaphorum.com/views-analysis-market-access/2021-market-access-prospects-for-france/
2021 market access prospects for Spain2021 will be the year when big market access changes – including the far wider use of health Share X2021 market access prospects for Spainhttps://pharmaphorum.com/views-analysis-market-access/2021-market-access-prospects-for-spain/
2021 market access prospects for GermanyThe market access landscape in Germany is particularly interesting in 2021, as a key component – AMNOG – Share X2021 market access prospects for Germanyhttps://pharmaphorum.com/views-analysis-market-access/2021-market-access-prospects-for-germany/
VPAS: Progress two years in and opportunities to improve over next three yearsIn the final instalment of our series reviewing the the 2019 Voluntary Scheme for Branded Medicines Pricing and Share XVPAS: Progress two years in and opportunities to improve over next three yearshttps://pharmaphorum.com/views-analysis-market-access/vpas-progress-two-years-in-and-opportunities-to-improve-over-next-three-years/
VPAS: Achievement so far on objectives for the economy and innovationIn the third part of this series taking stock of the 2019 Voluntary Scheme for Branded Medicines Pricing and Share XVPAS: Achievement so far on objectives for the economy and innovationhttps://pharmaphorum.com/views-analysis-market-access/vpas-achievement-so-far-on-objectives-for-the-economy-and-innovation/
VPAS: Achievements so far on affordabilityIn the second part of this series taking stock of the 2019 Voluntary Scheme for Branded Medicines Pricing Share XVPAS: Achievements so far on affordabilityhttps://pharmaphorum.com/views-analysis-market-access/vpas-achievements-so-far-on-affordability/
VPAS: Achievement so far on objectives for patientsThe UK has a voluntary agreement that was struck by the government and NHS England (now referred to Share XVPAS: Achievement so far on objectives for patientshttps://pharmaphorum.com/views-analysis-market-access/vpas-achievement-so-far-on-objectives-for-patients/
2021 market access prospects for ItalyItaly was working up big changes in market access throughout 2020 which will be implemented in 2021. In Share X2021 market access prospects for Italyhttps://pharmaphorum.com/views-analysis-market-access/2021-market-access-prospects-for-italy/
2021 – UK market access prospectsWith a new year comes the opportunity to think ahead for the market access landscape for the coming Share X2021 – UK market access prospectshttps://pharmaphorum.com/views-analysis-market-access/2021-uk-market-access-prospects/
